TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation (Disclosed): Preparation of (I) comprises cycloaddition of aryl compounds of formula (II) with oxime compounds of formula (III). Preferred Definitions:    R1 = CF3;    Q = oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, 1H-(1,2,3)triazol-4-yl, 2H-(1,2,3)triazol-4-yl, 1H-(1,2,3)triazol-5-yl or 1H-(1,2,3)triazol-1-yl (all substituted by -(alk)-C(O)-NHR7), or 1H-pyrrol-1-yl, 1H-pyrrol-2-yl, 1H-pyrrol-3-yl, 1H-imidazol-1-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, 1H-imidazol-5-yl, 1H-pyrazol-1-yl, 4-methyl-1H-pyrazol-1-yl, 4H-(1,2,4)triazol-4-yl, 4H-(1,2,4)triazol-3-yl, 1H-(1,2,4)triazol-3-yl, 1H-(1,2,4)triazol-5-yl, 1H-(1,2,4)triazol-1-yl, 2H-(1,2,3)triazol-2-yl, 1H-(1,2,3)triazol-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl or pyrimidin-4-yl (all optionally substituted);    Z = Q or -C(O)NR5R6, 1H-(1,2,4)triazol-1-yl;    R5 = H;    n = 1-3; and    alk = methylene (preferred) or 1,2-ethylene.    ACTIVITY - Antiparasitic; Insecticide; Acaricide; Nematocide; Anthelmintic.    MECHANISM OF ACTION - None given.    ADMINISTRATION - Administration of (I) is topical (0.05-1 ml/kg, preferably 0.1 ml/kg), oral, parenteral, peroral or subcutaneous.    SPECIFIC COMPOUNDS - 9 Compounds (I) are specifically claimed e.g. 5-(5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl)-3-methyl-thiophene-2-carboxylic acid ((2,2,2-trifluoro-ethylcarbamoyl)-methyl)-amide of formula (Ia), 5-(5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl)-3-methyl-thiophene-2-carboxylic acid (4-trifluoromethyl-thiazol-2-yl)-amide, 5-(5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl)-3-methyl-thiophene-2-carboxylic acid ethylcarbamoylmethyl-amide, 5-(5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl)-3-methyl-thiophene-2-carboxylic acid prop-2-ynylcarbamoylmethyl-amide and 5-(5-(3,5-dichloro-4-fluoro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl)-3-methyl-thiophene-2-carboxylic acid ((2,2,2-trifluoro-ethylcarbamoyl)-methyl)-amide.    EXAMPLE - Lithium hydroxide (LiOH) (3.2 g) was added to a solution of 5-(5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl)-3-methyl-thiophene-2-carboxylic acid ethyl ester (9.88 g) in a mixture of tetrahydrofuran (THF) and water (240 ml, 9:1). After 18 hours, LiOH (1.05 g) and THF (150 ml) were added. The reaction mixture was heated at 50 degrees C for 10 hours. Hydrochloric acid (2N) was added to the reaction mixture until pH 1-2 was obtained and worked up to give 5-(5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl)-3-methyl-thiophene-2-carboxylic acid (A). N,N-Diisopropylethylamine (0,246 ml) was added to a solution of (2,2,2-trifluoro-ethylcarbamoyl)-methyl-ammonium trifluoroacetate (0.170 g), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (0.270 g) and (A) (0.2 g) in dichloromethane (3 ml) at 0 degrees C. After 30 minutes the reaction was quenched with water and extracted three times with dichloromethane. The combined organic phases were washed with a saturated aqueous solution of sodium chloride and a saturated aqueous solution of sodium bicarbonate, dried and concentrated. The crude product was purified to give 5-(5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl)-3-methyl-thiophene-2-carboxylic acid ((2,2,2-trifluoro-ethylcarbamoyl)-methyl)-amide (8.73 g).